Fiducial Markers Market - Growth by Top Key Players, Segmentation and Forecast Analysis

The Research Report on “Fiducial Markers Market by Product (Metal Based Markers (Gold, Gold Combination) Polymer Markers), Cancer Type (Prostate, Lung, Breast), Modality (CT, CBCT, MRI, Ultrasound), End user (Hospitals, Outpatient Facilities) – Global Forecast to 2025″, is projected to reach USD 123 million by 2025 from USD 95 million in 2019, at a CAGR of 4.5% from 2019 to 2025.

Recent Developments:

• In 2019, Stratpharma AG (Switzerland) expanded its agreement with CIVCO (US) to distribute CIVCO’s radiotherapy solutions globally
• In 2019, IZI Medical Products (US) acquired the RadioMed division of IBA (Belgium), which manufactures the VISICOIL implantable fiducial markers
• In 2018, Nanovi A/S (Denmark) secured USD 2.23 million from existing investors to expand its business and introduce BioXmark in the European market

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180673710

Industry Segmentation In Detailed:

The metal-based FMs product segment to register significant growth over the forecast period

Based on product, the fiducial markers market is classified into metal-based markers, polymer-based markers, and others. The metal-based markers segment is expected to register significant growth over the forecast period of 2019 to 2025. The adoption of radiotherapy has increased in recent years due to its advantages, such as high precision & radiation control, reduced risk of side-effects, and minimal exposure of healthy tissues to radiation. As metal-based FMs are widely preferred for tumor localization, the rising adoption of radiotherapy procedures is expected to support market growth.

The CT/CBCT modality segment is projected to hold the largest share of the market during the forecast period of 2019 to 2025

On the basis of modality, the fiducial markers market is classified into CT/CBCT, MRI, ultrasound, and radiotherapy. CBCT is preferred for prostate and lung cancer indications, as it effectively detects changes in the position of cancer tumors. Thus, the rising incidences of prostate & lung cancer and the widespread use of CBCT in most developed countries for cancer diagnosis and treatment are the key factors driving the segment growth.

Prostate cancer segment to grow at the highest CAGR over the forecast period

Based on cancer type, the fiducial markers market is broadly segmented into prostate cancer, lung cancer, breast cancer, gastric cancer, and others. Among these, the prostate cancer segment is anticipated to register significant growth over the forecast period due to the rising incidences of prostate cancer globally and the high cure rate associated with radiotherapy. For instance, according to a study published in the Journal of Medical Imaging and Radiation Oncology, the use of EBRT in men suffering from prostate cancer showed a cure rate of ~95.5% for intermediate-risk prostate cancer.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=180673710

Leading Key Players and Analysis:

The major players in the market include CIVCO Radiotherapy (US), IZI Medical Products (US), Boston Scientific Corporation (US), Naslund Medical AB (Sweden), and IBA (Belgium). Other players are Best Medical International, Inc. (US), Nanovi A/S (Denmark), Carbon Medical Technologies (US), Eckert & Ziegler (Germany), Innovative Oncology Solutions (US), Medtronic (Ireland), and QFIX (US).

CIVCO Radiotherapy (US) dominated t­he global fiducial markers market in 2019. Its strong product portfolio and high geographic penetration are the ­key factors contributing to the leading position of this company in the market. In order to maintain its dominant position, the company develops both metal-based as well as polymer-based fiducial markers, such as FusionCoil, PolyMark, FlexiCoil, Align, and PointCoil. The company is also focusing on increasing its presence in developing countries to leverage high-growth opportunities.

Boston Scientific (US) held the second-largest market position in the global judicial markers industry. It became a key player in the market after the launch of its LumiCoil platinum fiducial marker. The company’s strong R&D capabilities and global manufacturing & distribution network are its major strengths.

Geographical Analysis in Detailed:

The fiducial markers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is projected to hold the largest share of the regional market for fiducial markers in 2019. This is attributed to the expansion of the target patient population, favorable reimbursement scenario, greater accessibility to radiotherapy procedures, and the presence of major players in this region.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=180673710

Lymphedema Diagnostics Market - Growth by Top Key Players and Forecast Analysis

The Research Report on “Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) – Global Forecasts to 2024″, is projected to reach USD 35 million by 2024 from USD 24 million in 2019, at a CAGR of 7.4%

Market Size Estimation;

Both top-down and bottom-up approaches were used to estimate and validate the total size of the lymphedema diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

• The key players in the industry and markets have been identified through extensive secondary research.
• The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
• All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation;

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145177203

Industry Segmentation In Detailed:

The lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market in 2018.

Based on technology, segmented into lymphoscintigraphy, magnetic resonance imaging (MRI), ultrasound imaging, computed tomography (CT), X-ray lymphography, bioimpedance analysis, and near-infrared fluorescence imaging. In 2018, the lymphoscintigraphy segment accounted for the largest share of the lymphedema diagnostics market. The noninvasive nature and easy reproducibility of this technology, and the fact that lymphoscintigraphy does not adversely affect the lymphatic vascular endothelium are some of the key advantages supporting the adoption of this technology.

The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018.

On the basis of disease type, segmented into cancer, inflammatory diseases, cardiovascular disease, and other diseases (congenital abnormalities, trauma-related conditions, infections, and filariasis). The cancer segment accounted for the largest share of the lymphedema diagnostics market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer-associated lymphedema and increasing awareness about early disease diagnosis.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=145177203

Leading Key Players and Analysis:

The major players operating in the lymphedema diagnostics therapy market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).

GE Healthcare (US) is one of the leading players in the global lymphedema diagnostics market. To sustain its leadership position and ensure its future growth, the company has been focusing on product launches and agreements, partnerships, and collaborations as its key strategies. The company has also been focusing on geographic expansions and the development of low-cost equipment specifically for developing nations. For instance, in May 2017, the company collaborated with the Government of Egypt to supply a wide range of technologies and train doctors, nurses, and technicians about advanced imaging systems in over 200 Egyptian hospitals. With a wide product portfolio and strong geographic presence, the company is expected to witness significant growth in the lymphedema diagnostics market in the coming years.

Geographical Analysis in Detailed:

The lymphedema diagnostics therapy market is segmented into four regional segments, namely, North America, Europe, the Asia Pacific, and the Rest of the World. The large share of North America can be attributed to factors such as the easy availability and rapid adoption of technologically advanced imaging systems; high incidence/prevalence of lymphedema; and the strong, well-established healthcare systems. The market in the Asia Pacific is expected to grow at the highest rate, followed by Europe.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=145177203

Cancer Diagnostics Market 2019 Key highlights, Segmentation, Overview and Forecast

The Research Report on Cancer Diagnostics Market Consist 89 market data tables and 37 figures spread through 197 pages and in-depth TOC, which covers Global Market overview, Major Key Players detailed Analysis, market opportunities, market risk, forecast for the next five years, major driving factors for the market as well as detailed analysis for CAGR, scope, research findings, leading key players marketing strategy to acquire major market in the form of revenue.

The cancer diagnostics market is highly competitive with many big and small players operating in different market segments.

Technological advancements in various fields such as biomarkers, imaging, biopsy, endoscopy; growing number of cancer cases, rapidly rise in geriatric population, awareness initiatives by governments, and increasing government funding are major factors driving the market growth. However, high capital investment and low benefit-cost ratio of biomarkers and dearth of skilled professionals pose restraints to the growth of this market. Improving healthcare infrastructure in emerging countries and growing demand of companion diagnostics offer growth opportunities for this market.

The global cancer diagnostics market is segmented based on technology, application, and region.

Download PDF (cancer diagnostics):

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121

The platform-based technology is further segmented into next-generation sequencing, microarrays, PCR, flow cytometry, in situ hybridization, immunohistochemistry, and others. Instrument-based cancer diagnostics is further segmented into imaging systems and biopsy.

Market-by Application

·         Breast Cancer

·         Lung Cancer

·         Colorectal Cancer

·         Melanoma

Cancer Diagnostics Market, by Product

# Platform-based

-          Next-generation Sequencing

-          Microarrays

-          PCR

-          Flow Cytometry

# Instrument-based

-          Imaging Instruments

-          Ultrasound

-          Mammography

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121

Based on region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the market.

Some of the major players in the global market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V.  (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.)

Single-cell Analysis Market 2019 Precise Outlook - Merck KGaA (Germany), Becton, Dickinson and Company (U.S.)

The Single-cell Analysis Market, by cell type, is segmented into human, animal, and microbial cells. the human cells segment is expected to account for the largest share of the market. The growing application areas of human stem cells and the rising incidence of diseases such as cancer are the major factors driving the growth of this segment.

Technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and increasing incidence and prevalence of chronic and infectious diseases are the major factors driving the growth of the market.

The objectives of this study are as follows:

• To define, describe, and forecast the market on the basis of products, cell type, technique, application, end user, and region.
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to four regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)

Speak to our analyst and gain crucial industry insights that will help your business grow:

https://www.marketsandmarkets.com/speaktoanalyst.asp?id=171955254

Browse and in-depth TOC on “Single-cell Analysis Market”.

107 — Tables

42 — Figures

175 — Pages

Single-cell Analysis Market, By Technique

• Flow Cytometry
• NGS
• PCR
• Microscopy
• Mass Spectrometry

Request for Free Sample Report @

https://www.marketsandmarkets.com/requestsample.asp?id=171955254

Single-cell Analysis Market, By Region:

• North America
• Europe
• Asia
• Rest of the World (RoW)

The Single-cell Analysis Market is highly fragmented in nature with several big as well as emerging players. Prominent players in this market include Merck KGaA (Germany), Becton, Dickinson and Company (U.S.), Promega Corporation (U.S.), Danaher Corporation (U.S.), General Electric Company (U.K.), Thermo Fisher Scientific Inc. (U.S.), Miltenyi Biotec (Germany), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Fluidigm Corporation (U.S.), NanoString Technologies, Inc. (U.S.), and Agilent Technologies (U.S.).

Growth Opportunities in HPV Testing and Pap Test Market

The HPV test is used to diagnose the infection caused by HPV that mutates a normal cell into a cancerous cell and further leads to the development of genital warts, abnormal cervical cells, or cervical cancer. The growth of the HPV testing and Pap test market is mainly attributed to the increasing number of cervical cancer cases, growing the aging population, increasing awareness of cervical cancer screening programs, and government initiatives and funding

According to Latest Market research report Published by MarketsandMarkets the “HPV Testing and Pap Test Market Size, Share, Demand and Growth Analysis, forecast” the Global Market is expected to reach $ 4.52 billion, at a CAGR of 6.6%

key players operating in the Global HPV Testing and Pap Test Market;

Key players in the market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.)

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371

Major Dynamics Impacting the HPV Testing and Pap Test Market;

· Growth Drivers:

1. An increasing number of cervical cancer cases and a growing aging population

2. Increasing awareness of cervical cancer screening programs

3. Government initiatives and funding.

· Restraints

1. Changes in regulatory guidelines for cervical cancer screening
2. HPV vaccination

Objectives of The Study-

• To define, describe, and segment the global HPV testing and Pap test market on the basis of test types, application, end user, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To analyze micro-markets with respect to individual growth trends, prospects, and contributions to the global HPV testing and Pap test market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players
• To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Request Research Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371

Global HPV Testing and Pap Test Market Segmentation:

Based on the application, the Pap test market is segmented into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is expected to grow at the highest CAGR during the forecast period, owing to the growing incidences of cervical cancer.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.

HPV Testing and Pap Test Market: Opportunities, Countries, Type, Application Technologies, Development Challenges and Forecast 2019

The Research Report on HPV Testing & Pap Test Market provides a detailed overview of major drivers, restraints, opportunities, challenges, current market trends, and strategies impacting the market along with estimates and forecasts of revenue.

Several factors such as increasing number of cervical cancer cases, growing aging population, increasing awareness of cervical cancer screening programs, and government initiative and funding are propelling the growth of the HPV testing and Pap test market.

Download PDF (HPV Testing & Pap Test Market):

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218189007

This research report segments the HPV Testing & Pap Test Market based on by test type, application, end user, and region.

An increasing number of cervical cancer cases and a growing aging population

Cervical cancer is the fourth most prevalent forms of cancer globally and is the most common cause of death among women (Source: Global Cancer Facts and figures). It has been estimated that 527,624 new cases of cervical cancer have emerged worldwide, while 265,653 women died due to cervical cancer in 2012. This figure is expected to reach to 609,270 new cases and 315,727 deaths by 2020.

Approximately 26,000 new cancers attributable to HPV occur each year, 18,000 among females and 8,000 among males (Source: CDC). The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. This, in turn, is expected to drive the HPV testing and Pap test market in the coming years.

Request Research Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371

HPV Testing & Pap Test Market Based on Application;

Based on the application, the Pap test market is segmented into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is expected to grow at the highest CAGR during the forecast period, owing to the growing incidences of cervical cancer.

Global HPV testing and Pap test Market, by Region

• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)

HPV Testing & Pap Test Market Based on end user;

On the basis of end user, the HPV testing and Pap test market is categorized into hospitals, laboratories, physician’s offices and clinics. The hospitals segment is projected to grow at the highest CAGR. This growth is attributed to the increasing patient volumes in hospitals, as most diagnostic tests are carried out in-house with advanced technologies and more accessibility.

Speak to Our Subject Expert:https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=214207371

HPV Testing & Pap Test Market’s Major Key Players:

Key players in the HPV testing and Pap test market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.).